Tarsus Pharmaceuticals, Inc.
TARSNASDAQHealthcare● Active
$59.22
$-0.06(-0.10%)
Market Cap$2.5B
P/E Ratio—
52W High$85.25
52W Low$38.51
Tarsus Pharmaceuticals, Inc.（TARS）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · TARS · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.45B | $0.18B | $0.02B | $0.03B | $0.06B |
| Cost of Revenue | $0.03B | $0.01B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.42B | $0.17B | $0.02B | $0.02B | $0.05B |
| Gross Margin %(computed) | 93.20% | 92.99% | 90.87% | 96.30% | 96.36% |
| Operating Expenses | |||||
| R&D Expenses | $0.06B | $0.05B | $0.05B | $0.04B | $0.04B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.04B | $0.03B |
| Total Operating Expenses | $0.49B | $0.29B | $0.16B | $0.09B | $0.07B |
| Operating Income | ($0.07B) | ($0.12B) | ($0.14B) | ($0.06B) | ($0.01B) |
| Operating Margin %(computed) | -15.72% | -65.90% | -820.53% | -242.92% | -21.32% |
| Interest Income | $0.02B | $0.02B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.01B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.06B) | ($0.12B) | ($0.14B) | ($0.06B) | ($0.01B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | ($0.00B) | $0.00B |
| Net Income | ($0.07B) | ($0.12B) | ($0.14B) | ($0.06B) | ($0.01B) |
| Net Margin %(computed) | -14.72% | -63.16% | -778.89% | -240.51% | -24.25% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.59 | $-3.07 | $-4.62 | $-2.52 | $-0.67 |
| Wtd Avg Shares | 0.04B | 0.04B | 0.03B | 0.02B | 0.02B |
| EBITDA | ($0.05B) | ($0.11B) | ($0.13B) | ($0.06B) | ($0.01B) |
| EBITDA Margin %(computed) | -11.88% | -58.20% | -754.69% | -231.27% | -23.60% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · B
深入了解Tarsus Pharmaceuticals, Inc.
关于Tarsus Pharmaceuticals, Inc.（TARS）损益表
Tarsus Pharmaceuticals, Inc.（TARS）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，TARS实现营收$0.45B，毛利润$0.42B（毛利率93.20%），净利润($0.07B)（净利率-14.72%）。
常见问题
TARS · 4 问Tarsus Pharmaceuticals, Inc.（TARS）2025财年营收为$0.45B，同比up146.7%。
TARS revenueTARS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08